^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG7775

    i
    Other names: RG-7775, RO6839921, RG7775, RG 7775, RO 6839921
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    MDM2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost5years
    Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. (PubMed, Invest New Drugs)
    There was not sufficient differentiation or improvement in the biologic or safety profile compared with oral idasanutlin to support continued development of RO6839921. NCT02098967.
    Clinical • P1 data • Journal
    |
    TP53 (Tumor protein P53) • GDF15 (Growth differentiation factor 15)
    |
    idasanutlin (RG7388) • RG7775